Patients with CLL on BTK inhibitor therapy are at risk of infections, which may in part be attributed to the biology of the disease itself and may also be partially caused by on- and off-target effects and drug-induced cytopenia [44,69]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.